We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Molecular Test Predicts Cancer Risk of Barrett's Esophagus

By LabMedica International staff writers
Posted on 02 Jun 2015
Print article
Image: Histopathology of Barrett\'s esophagus; the metaplasic epithelium of Barrett\'s esophagus is characterized by goblet cell, which stain blue with alcian blue (Photo courtesy of Nephron).
Image: Histopathology of Barrett\'s esophagus; the metaplasic epithelium of Barrett\'s esophagus is characterized by goblet cell, which stain blue with alcian blue (Photo courtesy of Nephron).
A molecular diagnostic test has been developed for predicting risk of progression from Barrett's esophagus to esophageal cancer approximately three to four years before the cancer progresses.

Barrett's esophagus (BE) is a condition that occurs when tissue lining the esophagus is replaced by tissue similar to the intestinal lining and it is associated with an increased risk of developing esophageal cancer.

Scientists at the University of North Carolina (Chapel Hill, NC, USA) and their colleagues conducted a case-control study to measure genetic instability, assessed by the mutational load (ML), in pre-progression BE tissue as a marker to predict progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Patients with BE were from three sites. Cases were BE patients with no dysplasia or low-grade dysplasia (LGD) at baseline, and who had HGD or EAC on a follow-up biopsy done at least one year later. Controls were matched 2:1, and had non-dysplastic BE or LGD at baseline and no progression of BE at follow-up. Formalin-fixed, paraffin-embedded tissue was micro-dissected for epithelium.

The presence of loss of heterozygosity (LOH) and microsatellite instability (MSI) was investigated using polymerase chain reaction and quantitative capillary electrophoresis of DNA extracted from each micro-dissected target. Of the 69 patients, there were 46 non-progressors and 23 progressors. The groups were similar in age, follow-up time, and mean number of micro-dissected targets. Both groups had a similar proportion of nondysplastic and LGD histology at index biopsy. The mean per-patient ML in the pre-progression biopsies was significantly higher in progressors compared to non-progressors. The BarreGen molecular test (Interpace Diagnostics; Parsippany, NJ, USA) had an overall accuracy of 95% in identifying patients who progressed to cancer from those who did not progress to cancer.

The authors concluded that the mutational load in pre-progression tissue of BE patients with no dysplasia or LGD, predicts progression to HGD or EAC. ML may have utility as a clinical biomarker in endoscopic surveillance of BE patients to predict progression to HGD and EAC approximately three to four years prior to the histological onset of HGD and EAC. The study was presented at Digestive Disease Week (DDW) held May 16–19, 2015, in Washington DC (USA).

Related Links:

University of North Carolina 
Interpace Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.